ASKG-915 is under clinical development by AskGene Pharma and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASKG-915’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASKG-915 overview

ASKG-915 is under development for the treatment of solid tumor, gastric cancer, esophageal cancer, pancreatic cancer and liver cancer, hepatocellular carcinoma, cervical cancer, ovarian epithelial cell carcinoma, colorectal cancer, and renal cell carcinoma (mainly clear cell type) ), gastric cancer or esophageal cancer, urothelial cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. It is a bi-specific fusion protein targeting IL 15 receptor and PD1. The drug candidate is being developed based on SmartKine cytokine prodrug technology platform. It is administered through intravenous route.

AskGene Pharma overview

AskGene Pharma is a biotechnology company. Its mission is to develop and bring our patients biosimilar versions of leading global biopharmaceuticals and biosuperior molecules with validated targets. The company is headquartered in Camarillo, Californi

For a complete picture of ASKG-915’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.